Bring Your Medicines to French Patients Sooner
Cevidra Guides Your Early Access Strategy in France

They trust us












What is an early access program?
Early Access Programs (formerly Cohort ATU) allow patients facing a therapeutic impasse to access medicines without marketing authorisation for a specific indication. Granted by HAS for one year, access applies to pre-MA products (with MA submission planned) or post-MA products not yet reimbursed by Social Security (AP1 and AP2).


How to apply for an early access?
Early Access applications are submitted digitally to the HAS by the pharmaceutical company, with evaluation taking up to 3 months. A local representative (“exploitant”) is required. Cevidra offers expert support: eligibility assessment, EA strategy, PTU review, labelling, and full assistance throughout the application process via the Sesame platform.






